{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:46:02Z","timestamp":1789753562169,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008131","name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the favorable effects of immunotherapies in multiple types of cancers, its complete success in CNS malignancies remains challenging. Recently, a successful clinical trial of cytokine-induced killer (CIK) cell immunotherapy in patients with glioblastoma (GBM) has opened a new avenue for adoptive cellular immunotherapies in CNS malignancies. Prompt from these findings, herein, we investigated whether dendritic cells (DC) in combination with cytokine-induced killer cells (DC-CIK) could also provide an alternative and more effective way to improve the efficacy of GBM treatment. The analysis showed that DC-CIK cells exerted a significant cytotoxic effect on the glioblastoma cell lines, especially with the phenotype of stem-like cells (GSCs). In addition, the increased specific lysis of these cells subsequent to DC-CIK co-culture was confirmed with confocal fluorescence microscope. The direct interactions between tumor and effector cells were found to be highly effective in GBM organoids (GBOs). Moreover, a significant increase in apoptosis and elevated levels of IFN-\u03b3 (and not TNF-\u03b1) secretion were observed as a targeting mechanism of DC-CIK cells against GBM cell models. Overall, we provide important preliminary evidence that DC-CIK cells may have potential in the treatment of CNS malignancies, particularly glioblastoma.<\/jats:p>","DOI":"10.1038\/s41598-024-84284-5","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T13:28:06Z","timestamp":1735910886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Annika Simone","family":"L\u00fcck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Melhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo G. H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarek","family":"Maciaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"84284_CR1","doi-asserted-by":"publisher","first-page":"153303382312041","DOI":"10.1177\/15330338231204198","volume":"22","author":"D Zhao","year":"2023","unstructured":"Zhao, D. et al. Current situation and prospect of adoptive cellular immunotherapy for malignancies. Technol. Cancer Res. Treat. 22, 15330338231204198 (2023).","journal-title":"Technol. Cancer Res. Treat."},{"key":"84284_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol. Cancer. 22, 28 (2023).","journal-title":"Mol. Cancer"},{"key":"84284_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13046-021-02184-2","volume":"40","author":"A Sharma","year":"2021","unstructured":"Sharma, A. & Schmidt-Wolf, I. G. H. 30 years of CIK cell therapy: Recapitulating the key breakthroughs and future perspective. J. Exp. Clin. Cancer Res. 40, 388 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"84284_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00262-023-03605-1","volume":"73","author":"A Sharma","year":"2024","unstructured":"Sharma, A. et al. Cytokine-induced killer (CIK) cells, successes and challenges: Report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy. Cancer Immunol. Immunother 73, 21 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"84284_CR5","doi-asserted-by":"publisher","first-page":"925633","DOI":"10.3389\/fimmu.2022.925633","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma. Front. Immunol. 13, 925633 (2022).","journal-title":"Front. Immunol."},{"key":"84284_CR6","first-page":"2793","volume":"15","author":"D Lu","year":"2023","unstructured":"Lu, D. et al. DC-CIK combined with chemotherapy on the efficacy, immune function, and life quality in colorectal cancer patients after radical resection. Am. J. Transl Res. 15, 2793\u20132801 (2023).","journal-title":"Am. J. Transl Res."},{"key":"84284_CR7","first-page":"4767","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Safety of dendritic cell and cytokine-induced killer (DC-CIK) cell-based immunotherapy in patients with solid tumor: a retrospective study in China. Am. J. Cancer Res. 13, 4767\u20134782 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"84284_CR8","first-page":"2587","volume":"141","author":"M Biondi","year":"2023","unstructured":"Biondi, M. et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden. Blood 141, 2587\u20132598 (2023).","journal-title":"Blood"},{"key":"84284_CR9","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.ymthe.2020.05.021","volume":"28","author":"MC Rotiroti","year":"2020","unstructured":"Rotiroti, M. C. et al. Targeting CD33 in Chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB Transposon System. Mol. Ther. 28, 1974\u20131986 (2020).","journal-title":"Mol. Ther."},{"key":"84284_CR10","doi-asserted-by":"crossref","unstructured":"Sharma, A., Guerrero-Cazares, H. & Maciaczyk, J. Editorial to special issue glioblastoma: Recapitulating the key breakthroughs and future perspective. Int. J. Mol. Sci. 24, (2023).","DOI":"10.3390\/ijms24032548"},{"key":"84284_CR11","doi-asserted-by":"crossref","unstructured":"Li, Y., Sharma, A., Maciaczyk, J. & Schmidt-Wolf, I. G. H. Recent development in NKT-Based immunotherapy of Glioblastoma: From bench to Bedside. Int. J. Mol. Sci. 23, (2022).","DOI":"10.3390\/ijms23031311"},{"key":"84284_CR12","doi-asserted-by":"publisher","first-page":"944452","DOI":"10.3389\/fimmu.2022.944452","volume":"13","author":"AB Mahmoud","year":"2022","unstructured":"Mahmoud, A. B. et al. Advances in immunotherapy for glioblastoma multiforme. Front. Immunol. 13, 944452 (2022).","journal-title":"Front. Immunol."},{"key":"84284_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan, A. C. et al. Management of glioblastoma: State of the art and future directions. CA Cancer J. Clin. 70, 299\u2013312 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"84284_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"84284_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459\u2013466 (2009).","journal-title":"Lancet Oncol."},{"key":"84284_CR16","doi-asserted-by":"publisher","first-page":"851628","DOI":"10.3389\/fonc.2022.851628","volume":"12","author":"MH Han","year":"2022","unstructured":"Han, M. H. et al. Efficacy of cytokine-induced killer cell immunotherapy for patients with pathologically pure glioblastoma. Front. Oncol. 12, 851628 (2022).","journal-title":"Front. Oncol."},{"key":"84284_CR17","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.18632\/oncotarget.12273","volume":"8","author":"DS Kong","year":"2017","unstructured":"Kong, D. S. et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget 8, 7003\u20137013 (2017).","journal-title":"Oncotarget"},{"key":"84284_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.15407\/exp-oncology.2023.03.282","volume":"45","author":"O Glavatskyi","year":"2023","unstructured":"Glavatskyi, O. et al. Dendritic cells in glioblastoma treatment: A modern view of the problem and own experience. Exp. Oncol. 45, 282\u2013296 (2023).","journal-title":"Exp. Oncol."},{"key":"84284_CR19","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/neuonc\/noad088","volume":"25","author":"KM Hotchkiss","year":"2023","unstructured":"Hotchkiss, K. M. et al. Dendritic cell vaccine trials in gliomas: Untangling the lines. Neuro Oncol. 25, 1752\u20131762 (2023).","journal-title":"Neuro Oncol."},{"key":"84284_CR20","doi-asserted-by":"publisher","first-page":"846674","DOI":"10.3389\/fonc.2022.846674","volume":"12","author":"B Hassel","year":"2022","unstructured":"Hassel, B., Niehusmann, P., Halvorsen, B. & Dahlberg, D. Pro-inflammatory cytokines in cystic glioblastoma: A quantitative study with a comparison with bacterial brain abscesses. With an MRI investigation of displacement and destruction of the brain tissue surrounding a glioblastoma. Front. Oncol. 12, 846674 (2022).","journal-title":"Front. Oncol."},{"key":"84284_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s004010100448","volume":"103","author":"C Hao","year":"2002","unstructured":"Hao, C. et al. Cytokine and cytokine receptor mRNA expression in human glioblastomas: Evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol. 103, 171\u2013178 (2002).","journal-title":"Acta Neuropathol."},{"key":"84284_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-021-03787-7","volume":"153","author":"DA Rosso","year":"2021","unstructured":"Rosso, D. A. et al. Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated gammadelta T lymphocytes. J. Neurooncol. 153, 403\u2013415 (2021).","journal-title":"J. Neurooncol"},{"key":"84284_CR23","doi-asserted-by":"crossref","unstructured":"Osuka, S. et al. N-cadherin upregulation mediates adaptive radioresistance in glioblastoma. J. Clin. Invest. 131, (2021).","DOI":"10.1172\/JCI136098"},{"key":"84284_CR24","doi-asserted-by":"crossref","unstructured":"Huang, M. et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci. Transl Med. 12, (2020).","DOI":"10.1126\/scitranslmed.aay7522"},{"key":"84284_CR25","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/ijc.29908","volume":"138","author":"M Schneider","year":"2016","unstructured":"Schneider, M. et al. A paired comparison between glioblastoma stem cells and differentiated cells. Int. J. Cancer. 138, 1709\u20131718 (2016).","journal-title":"Int. J. Cancer"},{"key":"84284_CR26","doi-asserted-by":"publisher","first-page":"104625","DOI":"10.1016\/j.isci.2022.104625","volume":"25","author":"AP Masilamani","year":"2022","unstructured":"Masilamani, A. P. et al. Calpain-mediated cleavage generates a ZBTB18 N-terminal product that regulates HIF1A signaling and glioblastoma metabolism. iScience 25, 104625 (2022).","journal-title":"iScience"},{"key":"84284_CR27","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","volume":"15","author":"F Jacob","year":"2020","unstructured":"Jacob, F., Ming, G. L. & Song, H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. Nat. Protoc. 15, 4000\u20134033 (2020).","journal-title":"Nat. Protoc."},{"key":"84284_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf, I. G., Negrin, R. S., Kiem, H. P., Blume, K. G. & Weissman, I. L. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 174, 139\u2013149 (1991).","journal-title":"J. Exp. Med."},{"key":"84284_CR29","doi-asserted-by":"publisher","first-page":"e1500","DOI":"10.1002\/cti2.1500","volume":"13","author":"J Pu","year":"2024","unstructured":"Pu, J., Sharma, A., Liu, T., Hou, J. & Schmidt-Wolf, I. G. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. Clin. Transl Immunol. 13, e1500 (2024).","journal-title":"Clin. Transl Immunol."},{"key":"84284_CR30","doi-asserted-by":"publisher","first-page":"629067","DOI":"10.3389\/fnins.2021.629067","volume":"15","author":"C Bremond Martin","year":"2021","unstructured":"Bremond Martin, C., Simon Chane, C., Clouchoux, C. & Histace, A. Recent trends and perspectives in cerebral organoids imaging and analysis. Front. Neurosci. 15, 629067 (2021).","journal-title":"Front. Neurosci."},{"key":"84284_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/labinvest.2015.140","volume":"96","author":"Y Lee","year":"2016","unstructured":"Lee, Y., Lee, J. K., Ahn, S. H., Lee, J. & Nam, D. H. WNT signaling in glioblastoma and therapeutic opportunities. Lab. Invest. 96, 137\u2013150 (2016).","journal-title":"Lab. Invest."},{"key":"84284_CR32","doi-asserted-by":"publisher","first-page":"778643","DOI":"10.3389\/fonc.2022.778643","volume":"12","author":"YX Gan","year":"2022","unstructured":"Gan, Y. X., Li, G. H., Ou, X., Wang, C. H. & Du, Q. H. Case report: Chemotherapy and radiotherapy combined with DC-CIK for pulmonary and mediastinal metastases from nasopharyngeal carcinoma. Front. Oncol. 12, 778643 (2022).","journal-title":"Front. Oncol."},{"key":"84284_CR33","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3233\/THC-230871","volume":"32","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Dendritic cell-cytokine killer combined with microwave ablation reduced recurrence for hepatocellular carcinoma compared to ablation alone. Technol. Health Care. 32, 1819\u20131834 (2024).","journal-title":"Technol. Health Care"},{"key":"84284_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.37796\/2211-8039.1414","volume":"13","author":"SM Huang","year":"2023","unstructured":"Huang, S. M., Jeng, L. B., Shyu, W. C. & Chen, H. Y. Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: a case report. Biomed. (Taipei). 13, 57\u201362 (2023).","journal-title":"Biomed. (Taipei)"},{"key":"84284_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14712598.2020.1728250","volume":"20","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin. Biol. Ther. 20, 601\u2013607 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"84284_CR36","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.21037\/tcr-23-603","volume":"12","author":"SW Van Gool","year":"2023","unstructured":"Van Gool, S. W. et al. Dendritic cell vaccination for glioblastoma multiforme patients: Has a new milestone been reached? Transl Cancer Res. 12, 2224\u20132228 (2023).","journal-title":"Transl Cancer Res."},{"key":"84284_CR37","doi-asserted-by":"crossref","unstructured":"Yusuf, S. et al. WNT\/beta-Catenin-mediated resistance to glucose deprivation in Glioblastoma Stem-like cells. Cancers (Basel) 14, (2022).","DOI":"10.3390\/cancers14133165"},{"key":"84284_CR38","doi-asserted-by":"crossref","unstructured":"Aretz, P. et al. Crosstalk between beta-catenin and CCL2 drives Migration of monocytes towards Glioblastoma Cells. Int. J. Mol. Sci. 23, (2022).","DOI":"10.3390\/ijms23094562"},{"key":"84284_CR39","doi-asserted-by":"crossref","unstructured":"Koch, K. et al. Overexpression of cystine\/glutamate antiporter xCT correlates with nutrient flexibility and ZEB1 expression in highly clonogenic glioblastoma stem-like cells (GSCs). Cancers (Basel) 13, (2021).","DOI":"10.3390\/cancers13236001"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84284-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T14:05:06Z","timestamp":1735913106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84284-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84284"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84284-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"734"}}